drugset / Trial / NCT05481658
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.
Timeline
- Start
- 2022-10-06
- Primary completion
- 2029-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diphencyprone | Small molecule | 0.04 % | Topical |
| Subject | Diphencyprone | Small molecule | 0.4 % | Topical |
Indications
No indication recorded.